The FDA is forc­ing a small an­tibi­ot­ic play­er back to the clin­ic for a new tri­al — 10 years af­ter first re­jec­tion

Mo­tif Bio $MTFB got a clear enough an­swer from the FDA on what reg­u­la­tors will need to see be­fore they re­con­sid­er an OK on their an­tibi­ot­ic iclaprim. And it’s not what their dwin­dling band of in­vestors want­ed to hear.

The lit­tle biotech con­fi­dent­ly re­port­ed Thurs­day morn­ing that the FDA is re­quir­ing an­oth­er clin­i­cal tri­al to clear up its stub­born con­cerns about the po­ten­tial for liv­er tox­i­c­i­ty — a worst case sce­nario that will once again sig­nif­i­cant­ly de­lay a pro­gram that has been try­ing to make a come­back at the agency for the past decade. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER